DISEASE SCANNER
Global Incurable Diseases Tracker
Ewing Sarcoma
The second most common bone tumor in children and adolescents, characterized by EWSR1-ETS gene fusions. Can occur in bone or soft tissue (extraosseous Ewing). Peak incidence in adolescence. Highly aggressive but chemotherapy-responsive.
25.0K
15
Symptoms
Treatment Options
Risk Factors
Diagnostic Methods
- 1Biopsy
- 2Imaging (CT, MRI, PET)
- 3Tumor markers
- 4Genetic testing
- 5Endoscopy
- 6Blood tests
- 7Screening programs
Prognosis
Localized disease has 70-75% 5-year survival with chemotherapy + local control. Metastatic disease at diagnosis has 20-30% long-term survival. Bone marrow metastases have poorer prognosis than lung metastases. Late relapses (>5 years) are rare. Survivors face long-term risks: secondary cancers, cardiac toxicity from doxorubicin, infertility from alkylating agents, and radiation-related complications. Intensive follow-up for 10+ years recommended.
Prevention
- Smoking cessation
- Sun protection
- Healthy diet
- Regular exercise
- Vaccination (HPV, HBV)
- Screening programs
- Limit alcohol
- Maintain healthy weight
Research Status
Multi-agent chemotherapy (vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide). Local control with surgery and/or radiation. Survival 70-80% for localized; <30% for metastatic. Research on novel agents ongoing.
Affected Countries
Sources
- https://www.cancer.gov
- https://www.who.int/cancer
- https://www.cancer.org
Medical Disclaimer
This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.